雪龍集團(603949.SH)網上路演時間26日14:00-17:00
格隆匯2月24日丨雪龍集團(603949.SH)公佈,公司首次公開發行不超過3747萬股人民幣普通股(A股)的申請已獲中國證券監督管理委員會證監許可﹝2020﹞131號文核准。
本次發行採用網下向符合條件的投資者詢價配售和網上向持有上海市場非限售A股股份和非限售存託憑證一定市值的社會公眾投資者定價發行相結合的方式進行。回撥機制啟動前,網下初始發行數量為2248.20萬股,佔本次發行總量的60%,網上初始發行數量為1498.80萬股,佔本次發行總量的40%。
網上路演時間:2020年2月26日(週三)14:00-17:00
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.